Who are Ramipril + Felodipine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Perindopril plus Amlodipine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ramipril-felodipine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Ramipril + Felodipine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ramipril + Felodipine (Ramipril + Felodipine) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: ACE inhibitor + calcium channel blocker combination. Area: Cardiovascular.

marketed ACE inhibitor + calcium channel blocker combination Angiotensin-converting enzyme (ACE) and L-type voltage-gated calcium channels Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Ramipril + Felodipine (Ramipril + Felodipine) — Sanofi. This combination lowers blood pressure by blocking angiotensin II formation (ramipril) and relaxing blood vessel smooth muscle (felodipine).

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ramipril + Felodipine TARGET	Ramipril + Felodipine	Sanofi	marketed	ACE inhibitor + calcium channel blocker combination	Angiotensin-converting enzyme (ACE) and L-type voltage-gated calcium channels
Perindopril plus Amlodipine	Perindopril plus Amlodipine	University of Abuja	marketed	ACE inhibitor + Calcium channel blocker combination	ACE (angiotensin-converting enzyme) and L-type calcium channels

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (ACE inhibitor + calcium channel blocker combination class)

Sanofi · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ramipril + Felodipine — Competitive Intelligence Brief. https://druglandscape.com/ci/ramipril-felodipine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab